SPY332.37-1.82 -0.54%
DIA274.42-1.48 -0.54%
IXIC11,085.25-32.28 -0.29%

Credit Suisse Maintains Neutral on Aimmune Therapeutics, Raises Price Target to $34.5

Credit Suisse analyst Evan Seigerman maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and raises the price target from $14 to $34.5.

 · 
Credit Suisse analyst Evan Seigerman maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and raises the price target from $14 to $34.5.